Cargando…

PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort

BACKGROUND: Current studies indicate that fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography ([(18)F]FDG PET/CT) is the most accurate imaging modality for the detection of relapsed locally advanced non-small cell lung cancer (NSCLC) after curatively intended chemoradiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Brose, Alexander, Michalski, Kerstin, Ruf, Juri, Tosch, Marco, Eschmann, Susanne M., Schreckenberger, Mathias, König, Jochem, Nestle, Ursula, Miederer, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190104/
https://www.ncbi.nlm.nih.gov/pubmed/37198668
http://dx.doi.org/10.1186/s40644-023-00567-6
_version_ 1785043219196674048
author Brose, Alexander
Michalski, Kerstin
Ruf, Juri
Tosch, Marco
Eschmann, Susanne M.
Schreckenberger, Mathias
König, Jochem
Nestle, Ursula
Miederer, Matthias
author_facet Brose, Alexander
Michalski, Kerstin
Ruf, Juri
Tosch, Marco
Eschmann, Susanne M.
Schreckenberger, Mathias
König, Jochem
Nestle, Ursula
Miederer, Matthias
author_sort Brose, Alexander
collection PubMed
description BACKGROUND: Current studies indicate that fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography ([(18)F]FDG PET/CT) is the most accurate imaging modality for the detection of relapsed locally advanced non-small cell lung cancer (NSCLC) after curatively intended chemoradiotherapy. To this day, there is no objective and reproducible definition for the diagnosis of disease recurrence in PET/CT, the reading of which is relevantly influenced by post radiation inflammatory processes. The aim of this study was to evaluate and compare visual and threshold-based semi-automated evaluation criteria for the assessment of suspected tumor recurrence in a well-defined study population investigated during the randomized clinical PET-Plan trial. METHODS: This retrospective analysis comprises 114 PET/CT data sets of 82 patients from the PET-Plan multi-center study cohort who underwent [(18)F]FDG PET/CT imaging at different timepoints for relapse, as suspected by CT. Scans were first analyzed visually by four blinded readers using a binary scoring system for each possible localization and the associated reader certainty of the evaluation. Visual evaluations were conducted repeatedly without and with additional knowledge of the initial staging PET and radiotherapy delineation volumes. In a second step, uptake was measured quantitatively using maximum standardized uptake value (SUVmax), peak standardized uptake value corrected for lean body mass (SULpeak), and a liver threshold-based quantitative assessment model. Resulting sensitivity and specificity for relapse detection were compared to the findings in the visual assessment. The gold standard of recurrence was independently defined by prospective study routine including external reviewers using CT, PET, biopsies and clinical course of the disease. RESULTS: Overall interobserver agreement (IOA) of the visual assessment was moderate with a high difference between secure (ĸ = 0.66) and insecure (ĸ = 0.24) evaluations. Additional knowledge of the initial staging PET and radiotherapy delineation volumes improved the sensitivity (0.85 vs 0.92) but did not show significant impact on the specificity (0.86 vs 0.89). PET parameters SUVmax and SULpeak showed lower accuracy compared to the visual assessment, whereas threshold-based reading showed similar sensitivity (0.86) and higher specificity (0.97). CONCLUSION: Visual assessment especially if associated with high reader certainty shows very high interobserver agreement and high accuracy that can be further increased by baseline PET/CT information. The implementation of a patient individual liver threshold value definition, similar to the threshold definition in PERCIST, offers a more standardized method matching the accuracy of experienced readers albeit not providing further improvement of accuracy.
format Online
Article
Text
id pubmed-10190104
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101901042023-05-18 PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort Brose, Alexander Michalski, Kerstin Ruf, Juri Tosch, Marco Eschmann, Susanne M. Schreckenberger, Mathias König, Jochem Nestle, Ursula Miederer, Matthias Cancer Imaging Research Article BACKGROUND: Current studies indicate that fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography ([(18)F]FDG PET/CT) is the most accurate imaging modality for the detection of relapsed locally advanced non-small cell lung cancer (NSCLC) after curatively intended chemoradiotherapy. To this day, there is no objective and reproducible definition for the diagnosis of disease recurrence in PET/CT, the reading of which is relevantly influenced by post radiation inflammatory processes. The aim of this study was to evaluate and compare visual and threshold-based semi-automated evaluation criteria for the assessment of suspected tumor recurrence in a well-defined study population investigated during the randomized clinical PET-Plan trial. METHODS: This retrospective analysis comprises 114 PET/CT data sets of 82 patients from the PET-Plan multi-center study cohort who underwent [(18)F]FDG PET/CT imaging at different timepoints for relapse, as suspected by CT. Scans were first analyzed visually by four blinded readers using a binary scoring system for each possible localization and the associated reader certainty of the evaluation. Visual evaluations were conducted repeatedly without and with additional knowledge of the initial staging PET and radiotherapy delineation volumes. In a second step, uptake was measured quantitatively using maximum standardized uptake value (SUVmax), peak standardized uptake value corrected for lean body mass (SULpeak), and a liver threshold-based quantitative assessment model. Resulting sensitivity and specificity for relapse detection were compared to the findings in the visual assessment. The gold standard of recurrence was independently defined by prospective study routine including external reviewers using CT, PET, biopsies and clinical course of the disease. RESULTS: Overall interobserver agreement (IOA) of the visual assessment was moderate with a high difference between secure (ĸ = 0.66) and insecure (ĸ = 0.24) evaluations. Additional knowledge of the initial staging PET and radiotherapy delineation volumes improved the sensitivity (0.85 vs 0.92) but did not show significant impact on the specificity (0.86 vs 0.89). PET parameters SUVmax and SULpeak showed lower accuracy compared to the visual assessment, whereas threshold-based reading showed similar sensitivity (0.86) and higher specificity (0.97). CONCLUSION: Visual assessment especially if associated with high reader certainty shows very high interobserver agreement and high accuracy that can be further increased by baseline PET/CT information. The implementation of a patient individual liver threshold value definition, similar to the threshold definition in PERCIST, offers a more standardized method matching the accuracy of experienced readers albeit not providing further improvement of accuracy. BioMed Central 2023-05-17 /pmc/articles/PMC10190104/ /pubmed/37198668 http://dx.doi.org/10.1186/s40644-023-00567-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Brose, Alexander
Michalski, Kerstin
Ruf, Juri
Tosch, Marco
Eschmann, Susanne M.
Schreckenberger, Mathias
König, Jochem
Nestle, Ursula
Miederer, Matthias
PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort
title PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort
title_full PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort
title_fullStr PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort
title_full_unstemmed PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort
title_short PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort
title_sort pet/ct reading for relapse in non-small cell lung cancer after chemoradiotherapy in the pet-plan trial cohort
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190104/
https://www.ncbi.nlm.nih.gov/pubmed/37198668
http://dx.doi.org/10.1186/s40644-023-00567-6
work_keys_str_mv AT brosealexander petctreadingforrelapseinnonsmallcelllungcancerafterchemoradiotherapyinthepetplantrialcohort
AT michalskikerstin petctreadingforrelapseinnonsmallcelllungcancerafterchemoradiotherapyinthepetplantrialcohort
AT rufjuri petctreadingforrelapseinnonsmallcelllungcancerafterchemoradiotherapyinthepetplantrialcohort
AT toschmarco petctreadingforrelapseinnonsmallcelllungcancerafterchemoradiotherapyinthepetplantrialcohort
AT eschmannsusannem petctreadingforrelapseinnonsmallcelllungcancerafterchemoradiotherapyinthepetplantrialcohort
AT schreckenbergermathias petctreadingforrelapseinnonsmallcelllungcancerafterchemoradiotherapyinthepetplantrialcohort
AT konigjochem petctreadingforrelapseinnonsmallcelllungcancerafterchemoradiotherapyinthepetplantrialcohort
AT nestleursula petctreadingforrelapseinnonsmallcelllungcancerafterchemoradiotherapyinthepetplantrialcohort
AT miederermatthias petctreadingforrelapseinnonsmallcelllungcancerafterchemoradiotherapyinthepetplantrialcohort